Study of Cabozantinib in Participants With Neuroendocrine Tumors Who Have Already Received Prior Treatment

Ipsen

Status: Enrolling

Conditions: Neuroendocrine Tumors

Study type: Observational

Funder types: Industry

Identifiers

NCT07314164

CLIN-60000-467

Details and patient eligibility

About

This study will assess how well cabozantinib works and how safe it is in adults with a type of cancer called neuroendocrine tumors (NETs).

These tumors can appear in all parts of the body. All participants in this study have already received at least one treatment that affects the whole body to help manage their cancer, but their disease has continued to grow.

The study will take place in regular hospitals and clinics in Germany and Austria.

It will follow about 150 participants who are taking cabozantinib as part of their usual care. Doctors will collect information from routine medical visits, tests, and scans to see how the cancer responds to treatment and how long participants stay on cabozantinib. They will also look at side effects and how the treatment affects participants' quality of life.

This is an observational study, which means that no extra tests or procedures will be done beyond what is normally used to care for participants with this condition.

Enrollment: 150 estimated patients

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

Participants can join the study if they meet all of the following conditions:

• Are 18 years or older and able to give informed consent.
• Have a physician-initiated decision to start treatment with cabozantinib for neuroendocrine tumors (NETs), made before joining the study.
• Have unresectable or metastatic, well-differentiated pancreatic (pNET) or extra-pancreatic neuroendocrine tumors (epNET).
• Have already received at least one prior systemic therapy, other than somatostatin analogues.
• Have signed a written informed consent form.

Exclusion criteria

Participants cannot join the study if:

• They are currently participating in an interventional clinical trial, or have done so within the last 3 months before joining this study.
• They have a contraindication to cabozantinib treatment, based on the product's official prescribing information.